Roche Diagnostics Gmbh

Molmed Spa

Boehringer Mannheim Gmbh

Claudio Bordignon

Fulvio Mavilio

Catia Traversari

Georg Tiefenthaler

Bernhard Goller

Ruediger Rueger

Antonio Lambiase

The present invention provides conjugates of cytokines and targeting peptides that is able to bind to a receptor expressed on tumor-associated vessels or to a component of the extracellular matrix associated to the tumor vessels, for treatment of malignant pleural mesothelioma. In particular, the invention provides conjugates comprising the cytokine TNF linked to a peptide containing the NGR motif. The invention further provides pharmaceutical compositions comprising such conjugate and pharmaceutical formulations comprising conjugates dissolved in appropriate buffers.

Conjugates for the treatment of mesothelioma

A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen.

Antigen transduced T cells used as a delivery system for antigens

A titer of retroviral vectors of at least about 10 colony-forming units/ml cell culture supernatants is obtained using an amphotropic retroviral packaging cell line which contains functional gag, pol and env genes integrated into the genome in which the expression of the genes gag and pol is regulated independently of the expression of the env genes, wherein the genome of the said cell line contains one or two functionally active env genes.

Amphotropic retrovirus packaging cell line, process for its production and use thereof

In the course of therapy following an allogeneic bone marrow transplant (allo-BMT) in which lymphocytes were removed from the transplant, donor lymphocytes are introduced after a delay to reconstitute immunity in the patient. According to the invention, these donor lymphocytes are transduced with a detectable cell surface marker and a suicide gene prior to introducing them into the patient. Introduction of these transduced lymphocytes after allo-BMT, serves to treat or prevent complications from the BMT, including disease relapse, reactivation of viral infection and Graft versus Host disease.

Growing community of inventors

Milan, Italy

Claudio Bordignon